Scientists have identified a novel two-pronged treatment method, offering significant potential for patients battling advanced prostate cancer. Experts at The Institute of Cancer Research, London, ...
Hosted on MSN
Prostate cancer breakthrough: life-extending drug will be offered to thousands of men within weeks
Thousands of men with prostate cancer are set to get a life-extending drug on the NHS within weeks – in a breakthrough that could give families precious extra years together. For the first time, ...
Thousands of men in England living with advanced prostate cancer are poised to benefit from a new life-extending drug, talazoparib, which has been approved for NHS use. The once-daily pill, with its ...
The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...
Morning Overview on MSN
New prostate cancer immunotherapy slashes biomarkers by up to 99%
An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...
A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage trial investigated a form of radiotherapy on patients who had stopped ...
A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests. The imaging test highlights aggressive prostate cancer cells, reducing the ...
LOS ANGELES--(BUSINESS WIRE)--The Prostate Cancer Foundation (PCF) celebrated groundbreaking progress and innovation in the fight against prostate cancer at its 32 nd Annual PCF Scientific Retreat, ...
Add Yahoo as a preferred source to see more of our stories on Google. The once-daily pill, with its brand name Talzenna and produced by Pfizer, offers a crucial at-home treatment option after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results